Abstract
Aberrant epigenetic modifications are an early event in carcinogenesis, with the epigenetic landscape continuing to change during tumor progression and metastasis—these observations suggest that specific epigenetic modifications could be used as diagnostic and prognostic biomarkers for many cancer types. DNA methylation, post-translational histone modifications, and non-coding RNAs are all dysregulated in cancer and are detectable to various degrees in liquid biopsies such as sputum, urine, stool, and blood. Here, we will focus on the application of liquid biopsies, as opposed to tissue biopsies, because of their potential as non-invasive diagnostic tools and possible use in monitoring therapy response and progression to metastatic disease. This includes a discussion of septin-9 (SEPT9) DNA hypermethylation for detecting colorectal cancer, which is by far the most developed epigenetic biomarker assay. Despite their potential as prognostic and diagnostic biomarkers, technical issues such as inconsistent methodology between studies, overall low yield of epigenetic material in samples, and the need for improved histone and non-coding RNA purification methods are limiting the use of epigenetic biomarkers. Once these technical limitations are overcome, epigenetic biomarkers could be used to monitor cancer development, disease progression, therapeutic response, and recurrence across the entire cancer care continuum.
Highlights
Cancer has been referred to as “cellular chaos”
Regardless of whether aberrant epigenetic modifications are required for carcinogenesis, certain modifications are consistently dysregulated among cancers
There are several types of non-coding RNAs, such as small nucleolar RNAs, and short interfering RNAs; but microRNAs and long non-coding RNAs have been the most extensively characterized in cancer [38,39]
Summary
Cancer has been referred to as “cellular chaos”. This is an appropriate description for a disease which is characterized by uncontrolled cell proliferation and avoiding the host’s strategies to eliminate aberrant cells. The term epigenotype was first coined by C.H. Waddington in 1942 to describe the heritable alterations in gene expression which affect phenotype and do not change the DNA sequence itself [3]. Epigenetic modifications are key regulators of gene expression and contribute to genomic stability/chromatin structure. Regardless of whether aberrant epigenetic modifications are required for carcinogenesis, certain modifications are consistently dysregulated among cancers. This presents an opportunity to use these modifications as biomarkers for screening, detection, prediction of therapeutic response, and relapse surveillance
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have